Evaluating the impact of new anticoagulants in the hospital setting
The short-comings of current anticoagulants have led to the development of newer, albeit more expensive, oral alternatives.
Objective: To explore the potential impact the new anticoagulants dabigatran and rivaroxaban in the local hospital setting, in terms of utilisation and subsequent costing.
Method: A preliminary costing analysis was performed based on a prospective 2-week clinical audit (29th June - 13th July 2009). Data regarding current anticoagulation management were extracted from the medical files of patients admitted to Ryde Hospital. To model potential costing implications of using the newer agents, the reported incidence of VTE/stroke and bleeding events were obtained from key clinical trials.
Results: Data were collected for 67 patients treated with either warfarin (n=46) or enoxaparin (n=21) for prophylaxis of VTE/stroke. At least two-thirds of all patients were deemed suitable candidates for the use of newer oral anticoagulants (by current therapy: warfarin: 65.2% (AF), 34.8% (VTE); enoxaparin: 100%, (VTE)). The use of dabigatran in VTE/stroke prevention was found to be more cost-effective than warfarin and enoxaparin due to significantly lower costs of therapeutic monitoring and reduced administration costs. Rivaroxaban was more cost-effective than warfarin and enoxaparin for VTE/stroke prevention when supplier-rebates (33%) were factored into costing.
Conclusion: This study highlights the potential cost-effectiveness of newer anticoagulants, dabigatran and rivaroxaban, compared to warfarin and enoxaparin. These agents may offer economic advantages, as well as clinical benefits, in the hospital-based management of anticoagulated patients.
2. Serebruany V, Makarov L. Praugrel for arterialcoronary thrombosis. Drugs Today (Barc). 2009;45(2):83-91.
3. Pelletier M, Bugeaud R, Ibrahim R, Morency G, Kouz S. Successful thrombolysis of a stroke with a pulmonary embolism in young woman. J Emerg Med. 2010;39(4):443-448.
4. Bhatia V, Arora P, Parida AK, Singh G, Kaul U. Air travel and pulmonary embolism: “economy class syndrome”. Indian Heart J. 2008;60(6):608-611.
5. Konstantinides S. Clinical practice, acute pulmonary embolism. N Engl J Med. 2008;359(26):2804-2813.
6. Bauer KA. New anticoagulants. Curr Opin Hematol. 2008;15(5):509-515.
7. Bauer KA. New anticoagulants. Hematology Am Soc Hematol Educ Program. 2006;450-456.
8. Haideri N, Patel H. New anticoagulents & clinical trials. Mo Med. 2009;106(1):60-64.
9. Khoo CW, Tay KH, Shantsila E, Lip GY. Novel oral anticoagulents. Int J Clin Pract. 2009;63(4):630-641.
10. Dentali F, Crowther MA. Management of excessive anticoagulant effect due to vitamin K antagonists. Hemtaology Am Soc Hematol Educ Program. 2008;266-270.
11. Fang MC. Antithrombotic therapy for the treatment of atrial fibrillation in the elderly. J Interv Card Electrophysiol. 2009;25(1):19-23.
12. Uncu H. A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflammatory agent in the treatment of superficial vein thrombosis. Phlebology. 2009;24(2):56-60.
13. Alban S. Pharmacology of heparins and direct anticoagulants. Hamostaseologie. 2008;28(5):400-420.
14. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatron compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF-III): randomised controlled trial. Lancet. 2003;362:1691-1698.
15. Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs. 2002;11(3):397-407.
16. Weitz JI, Hirsh J. New anticoagulant drugs. Chest. 2001;119:95S-107S.
17. Graff J, von Hentig N, Misselwitz F, Kubitza D, Becka M, Breddin Hans-Klaus, Harder S. (2007). Effects of the oral, direct factor Xa inhibitor Rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol. 2007;47:1398.
18. Bayer plc. Xarelto 10 mg film-coated tablets. Electronic Medicines Compendium. 2008. http://emc.medicines.org.uk/ (Accessed 04/2009)
19. Haas S. New anticoagulants - towards the development of an “ideal” anticoagulant. Vasa. 2009;38(1):13-29.
20. Depasse FBJ, Mnich J, Le Flem L, Gerotziafas GT, Samama MM. Effect of BAY 59-7939-a novel, oral, direct factor Xa inhibitor-on clot-bound factor Xa activity in vitro. Presented at XXth Congress of the International Society on Thrombosis and Homeostasis; August 6-12, 2005; Sydney Australia.
21. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358: 2776-2786.
22. Therapeutic Guidelines: Cardiovascular. Version 4. Melbourne: Therapeutic Guidelines Limited; 2003.
23. Medicare Australia Annual Report 2007-2008. ACT: Blue Star Print Group; 2008.
24. Australian public health data (2007-2008). Persons employed in health and community services. Australian Institute of Health and Welfare, 2008. http://www.aihw.gov.au/publications/hwl/hwl4310677/table_1_8_occupation_by_weekly_income.xls - 2009-03-24 (Accessed 07/2009)
25. Medicare Benefits Schedule July 2009. ACT: Commonwealth Government of Australia; 2009.
26. Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther. 2009;31(1):194-212.
27. Australian hospital statistics (2007-2008). Australian Institute of Health and Welfare, 2008.
28. Wallentin L, Ezekowitz M, Simmers TA, et al; PETRO-investigators. Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation: a dose finding trial with comparison to warfarin. Eur Heart J. 2005;26(suppl):482.
29. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009;101(1):77-85.
30. Ageno W. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. Expert Rev Cardiovasc Ther. 2009;7(6):569-576.
31. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673-1680.
32. Broderick JP. Stroke therapy in the year 2025: burden, breakthroughs, and barriers to progress. Stroke. 2004;35(1):205-211.
33. Petersen P. Ximelagatran versus warfarin for stroke prevention in patients of nonvalvular atrial fibrillation. J. Amer. Coll. Cardiol. 2003;41:1445-1451.
34. Wells PS. Interactions of warfarin with drugs and food. Annals Intern Med. 1994;121:676-683.
35. Hylek EM. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 198;279:657-662.
36. Carabballo PJ. Long-term use of oral anticoagulation and the risk of fracture. Arch Intern Med. 1999;159:1750-1756.
37. Waldo AL. Stroke prevention in atrial fibrillation. JAMA. 2003;290:1093-1095.
38. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin. BMJ. 2000;321:1170-1171.
39. Diener H-C, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Pasquale GD, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischeamic attack or stroke: a subgroup analysis of RE-LY trial. Lancet Neurol. 2010;9:1157-1163.
40. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener, H-C, Joyner CD, Wallentin L. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Eng J Med. 2009;361:1139-1151.
41. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008;112:2242-2247.
42. Patel MR. Rivaroxaban – Once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340-347.
43. National Institute of Health and Clinical Excellence. Final appraisal determination. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. http://www.nice.org.uk/nicemedia/pdf/DabigatranFAD.pdf. (Accessed 07/2009)
44. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29-38.
45. Bauersachs RM. New Anticoagulants. Hamostaseologie. 2008;28(1-2):21-26.
46. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. (2010). Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. Ann Intern Med. 2011;154(1):1-11.
47. McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeconomics. 2009;27(10):829-846.
The authors hereby transfer, assign, or otherwise convey to Pharmacy Practice: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print pr epublish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to Pharmacy Practice with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.